Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors

Cancer Biology and Therapy

Volumn 16, Issue 1, 2015, Pages 43-51

  Samulitis, Betty K ^a   Pond, Kelvin W ^a   Pond, Erika ^a   Cress, Anne E ^a,b   Patel, Hitendra ^a,b   Wisner, Lee ^a   Patel, Charmi ^a   Dorr, Robert T ^a,b   Landowski, Terry H ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

chemotherapy resistance; gemcitabine; HDAC; invasion; Pancreatic cancer

Indexed keywords

AZACITIDINE; CLADRIBINE; CLOFARABINE; CYTARABINE; CYTIDINE DEAMINASE; DECITABINE; DOXORUBICIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; IRINOTECAN; PACLITAXEL; PYRIMIDINE NUCLEOSIDE; VINORELBINE TARTRATE; VORINOSTAT; ANTINEOPLASTIC ANTIMETABOLITE; CHROMATIN; DEOXYCYTIDINE; HISTONE DEACETYLASE;

ARTICLE; CANCER INHIBITION; CELL JUNCTION; CELL STRUCTURE; CHEMOTHERAPY; COLLATERAL SENSITIVITY; CONTROLLED STUDY; CROSS RESISTANCE; DNA MICROARRAY; DNA SYNTHESIS; DRUG DETOXIFICATION; DRUG EXPOSURE; DRUG RESISTANCE; DRUG-RESISTANT CELL LINE; FIBROBLAST; GEMCITABINE-RESISTANT CELL LINE; GENE ONTOLOGY; HETEROCHROMATIN; HUMAN; HUMAN CELL; HYPERSENSITIVITY; METABOLISM; METASTASIS POTENTIAL; MTT ASSAY; PANCREAS CARCINOMA; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; CELL MOTION; CHROMATIN; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PANCREAS TUMOR; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL MOVEMENT; CHROMATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; PANCREATIC NEOPLASMS; PHENOTYPE;

EID: 85003046547     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.986967     Document Type: Article

References (30)

1. Stathis A, Moore MJ. Advanced pancreatic carcinoma:current treatment and future challenges. Nat Rev Clin Oncol 2010; 7:163-72; http://dx.doi.org/10.1038/nrclinonc.2009.236
2. Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene 2013; 32:5253-60; PMID:23416985; http://dx.doi.org/10.1038/onc.2013.29
3. Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE. Nucleoside anticancer drugs:the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003; 22:7524-36; PMID:14576856; http://dx.doi.org/10.1038/sj.onc.1206952
4. Giroux V, Iovanna J, Dagorn JC. Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J 2006; 20:1982-91; PMID:17012250; http://dx.doi.org/10.1096/fj.06-6239com
5. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004; 10:2307-18; PMID:15073106; http://dx.doi.org/10.1158/1078-0432.CCR-1183-3
6. Liau SS, Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008; 14:1470-7; PMID:18316571; http://dx.doi.org/10.1158/1078-0432.CCR-07-1450
7. Farrell JJ, Bae K, Wong J, Guha C, Dicker AP, Elsaleh H. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer:RTOG 9704. Pharmacogenomics J 2012; 12:395-403
8. Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst 2014; 106:djt347; PMID:24301456; http://dx.doi.org/10.1093/jnci/djt347
9. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-6; PMID:18772397; http://dx.doi.org/10.1126/science.1164368
10. Penchev VR, Rasheed ZA, Maitra A, Matsui W. Heterogeneity and targeting of pancreatic cancer stem cells. Clin Cancer Res 2012; 18:4277-84; PMID:22896694; http://dx.doi.org/10.1158/1078-0432.CCR-11-3112
11. Chang DK, Grimmond SM, Biankin AV. Pancreatic cancer genomics. Curr Opin Genet Dev 2014; 24:74-81; http://dx.doi.org/10.1016/j.gde.2013.12.001
12. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17:500-3
13. Cui Y, Brosnan JA, Blackford AL, Sur S, Hruban RH, Kinzler KW, Vogelstein B, Maitra A, Diaz LA Jr, Iacobuzio-Donahue CA, et al. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin Cancer Res 2012; 18:6519-30; PMID:22753594; http://dx.doi.org/10.1158/1078-0432.CCR-12-0827
14. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-61; PMID:19460966; http://dx.doi.org/10.1126/science.1171362
15. Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, Frei E3rd. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990; 247:1457-61; PMID:2108497; http://dx.doi.org/10.1126/science.2108497
16. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25:25-9
17. Alexa A, Rahnenfuhrer J, Lengauer T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 2006; 22:1600-7; PMID:16606683; http://dx.doi.org/10.1093/bioinformatics/btl140
18. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14:3629-37; http://dx.doi.org/10.1245/s10434-007-9583-5
19. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69:2400-7; PMID:19276344; http://dx.doi.org/10.1158/0008-5472.CAN-08-4312
20. Gungor C, Zander H, Effenberger KE, Vashist YK, Kalinina T, Izbicki JR, Yekebas E, Bockhorn M. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res 2011; 71:5009-19; PMID:21632553; http://dx.doi.org/10.1158/0008-5472.CAN-11-0036
21. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313-23; PMID:18371365; http://dx.doi.org/10.1016/j.stem.2007.06.002
22. Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69:6704-12; PMID:19654291; http://dx.doi.org/10.1158/0008-5472.CAN-09-1298
23. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69:5820-8; PMID:19584296; http://dx.doi.org/10.1158/0008-5472.CAN-08-2819
24. Groger CJ, Grubinger M, Waldhor T, Vierlinger K, Mikulits W. Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS One 2012; 7:e51136
25. Bera A, VenkataSubbaRao K, Manoharan MS, Hill P, Freeman JW. A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer. PLoS One 2014; 9:e106343; http://dx.doi.org/10.1371/journal.pone.0106343
26. Glynn SA, Gammell P, Heenan M, O’Connor R, Liang Y, Keenan J, Clynes M. A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. Br J Cancer 2004; 91:1800-7; PMID:15505620; http://dx.doi.org/10.1038/sj.bjc.6602221
27. Wu A, Loutherback K, Lambert G, Estevez-Salmeron L, Tlsty TD, Austin RH, Sturm JC. Cell motility and drug gradients in the emergence of resistance to chemotherapy. Proc Natl Acad Sci U S A 2013; 110:16103-8; http://dx.doi.org/10.1073/pnas.1314385110
28. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141:69-80; PMID:20371346; http://dx.doi.org/10.1016/j.cell.2010.02.027
29. Congdon LM, Pourpak A, Escalante AM, Dorr RT, Landowski TH. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochem.Pharmacol 2008; 75:883-90
30. Watson M, Chow S, Barsyte D, Arrowsmith C, Shankey TV, Minden M, Hedley D. The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytometry. Cytometry A 2014; 85:78-87; PMID:24038859; http://dx.doi.org/10.1002/cyto.a.22344